Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma and High-Grade Glioma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2018
At a glance
- Drugs Crizotinib (Primary) ; Dasatinib (Primary)
- Indications Glioma
- Focus Adverse reactions
- 08 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 06 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Mar 2018.
- 31 Jan 2018 Planned End Date changed from 1 Oct 2020 to 1 Nov 2020.